We found mice treated with anti-VSIG4 or anti-SPP1 antibody alone exhibited slower tumor growth, and combination therapy with VSIG4 and SPP1 blockade synergistically enhanced anti-tumor activity without affecting body weight (Fig. 5J-M). This evidence concerns the gene VSIG4 and neoplasm.